Table 1.
Association between clinical characteristics and c-MYC amplification or polysomy for chromosome 8.
| Total Cases |
c-MYC amplificationa | c-MYC amplificationb | Polysomy for chromosome 8c | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||
| ≥ 2 c-MYC/CEP8 copies | ≥ 1.5 c-MYC/CEP8 copies | ≥ 4 CEP8 copies | ||||||||
|
|
|
|
||||||||
| No | Yes | P* | No | Yes | P* | No | Yes | p* | ||
| Patient age in years | 0.479 | 0.382 | <0.001 | |||||||
| <50 | 30 | 20 (66.7) | 10 (33.3) | 10 (33.3) | 20 (66.7) | 27 (90.0) | 3 (10.0) | |||
| 50–59 | 26 | 17 (65.4) | 9 (34.6) | 10 (38.5) | 16 (61.5) | 19 (73.1) | 7 (26.9) | |||
| 60–69 | 28 | 23 (82.1) | 5 (17.9) | 15 (53.6) | 13 (46.4) | 13 (46.4) | 15 (53.6) | |||
| ≥ 70 | 13 | 9 (69.2) | 4 (30.8) | 4 (30.8) | 9 (69.2) | 13 (100.0) | 0 (0.0) | |||
| Race | 0.430 | 0.489 | 0.860 | |||||||
| Caucasian | 86 | 59 (68.6) | 27 (31.4) | 36 (41.9) | 50 (58.1) | 64 (74.4) | 22 (25.6) | |||
| African American | 6 | 5 (83.3) | 1 (16.7) | 1 (16.7) | 5 (83.3) | 4 (66.7) | 2 (33.3) | |||
| Otherd | 5 | 5 (100.0) | 0 (0.0) | 2 (40.0) | 3 (60.0) | 4 (80.0) | 1 (20.0) | |||
| GOG performance status | 1.000 | 0.321 | 0.775 | |||||||
| Asymptomaticscore 0/1 | 77 | 55 (71.4) | 22 (28.6) | 33 (42.9) | 44 (57.1) | 58 (75.3) | 19 (24.7) | |||
| Symptomaticscore 2 | 20 | 14 (70.0) | 6 (30.0) | 6 (30.0) | 14 (70.0) | 14 (70.0) | 6 (30.0) | |||
| Tumor stage | 0.646 | 0.287 | 0.633 | |||||||
| Stage III | 60 | 44 (73.3) | 16 (26.7) | 27 (45.0) | 33 (55.0) | 43 (71.7) | 17 (28.3) | |||
| Stage IV | 37 | 25 (67.6) | 12 (32.4) | 12 (32.4) | 25 (67.6) | 29 (78.4) | 8 (21.6) | |||
| Histologic cell type | 0.179 | 0.051 | 0.234 | |||||||
| Serous | 72 | 53 (73.6) | 19 (26.4) | 29 (40.3) | 43 (59.7) | 51 (70.8) | 21 (29.2) | |||
| Endometrioid | 9 | 8 (88.9) | 1 (11.1) | 7 (77.8) | 2 (22.2) | 9 (100.0) | 0 (0.0) | |||
| Clear cell | 2 | 1 (50.0) | 1 (50.0) | 0 (0.0) | 2 (100.0) | 2 (100.0) | 0 (0.0) | |||
| Mucinous | 3 | 1 (33.3) | 2 (66.7) | 1 (33.3) | 2 (66.7) | 3 (100.0) | 0 (0.0) | |||
| Other cell types | 11 | 6 (54.5) | 5 (45.5) | 2 (18.2) | 9 (81.8) | 7 (63.6) | 4 (36.4) | |||
| Tumor grade | 0.453 | 0.386 | 0.652 | |||||||
| 1well differentiated | 6 | 3 (50.0) | 3 (50.0) | 2 (33.3) | 4 (66.7) | 5 (83.3) | 1 (16.7) | |||
| 2moderately differentiated | 44 | 31 (70.5) | 13 (29.5) | 21 (47.7) | 23 (52.3) | 34 (77.3) | 10 (22.7) | |||
| 3poorly differentiated/not graded | 47 | 35 (74.5) | 12 (25.5) | 16 (34.0) | 31 (66.0) | 33 (70.2) | 14 (29.8) | |||
| Measurable disease | 1.000 | 0.837 | 0.019 | |||||||
| Non-measurable | 44 | 31 (70.5) | 13 (29.5) | 17 (38.6) | 27 (61.4) | 38 (86.4) | 6 (13.6) | |||
| Measurable | 53 | 38 (71.7) | 15 (28.3) | 22 (41.5) | 31 (58.5) | 34 (64.2) | 19 (35.8) | |||
| Treatment | 1.000 | 1.000 | 1.000 | |||||||
| Cyclophos + cisplatin | 52 | 37 (71.2) | 15 (28.8) | 21 (40.4) | 31 (59.6) | 39 (75.0) | 13 (25.0) | |||
| Paclitaxel + cisplatin | 45 | 32 (71.1) | 13 (28.9) | 18 (40.0) | 27 (60.0) | 33 (73.3) | 12 (26.7) | |||
| Total | 97 | 69 (71.1) | 28 (28.9) | 39 (40.2) | 58 (59.8) | 72 (74.2) | 25 (25.8) | |||
c-MYC amplification was categorized as ‘No' when tumors had <2 copies of c-MYC/CEP8 per cell or ‘Yes' when tumors had ≥ 2 copies of c-MYC/CEP8 per cell. Results presented as cases with row percentages in parentheses.
c-MYC amplification was categorized as ‘No' when tumors had < 1.5 copies of c-MYC/CEP8 per cell or ‘Yes’ when tumors had ≥ 1.5 copies of c-MYC/CEP8 per cell. Results presented as cases with row percentages in parentheses.
Polysomy for chromosome 8 was categorized as ‘No' when tumors had < 4 copies of CEP8 per cell or ‘Yes' when tumors had ≥ 4 copies of CEP8 per cell. Results presented as cases with row percentages in parentheses.
Other includes two Asians, one American Indian, and two with an unspecified race.
p-value based on Fisher's Exact Test.